The Saudi Arabia veterinary vaccine market was valued at US$30.724 million in 2020.
Saudi Arabia's Veterinary market growth is attributed to the increase in awareness of veterinary healthcare improved animal husbandry measures, and equivalent increases in animal ownership are all key drivers for the fast-growing animal vaccines market penetration in the country. According to the Ministry of Environment, Water and Agriculture, there were roughly 1.4 million camels in Saudi Arabia, of which 14 percent are officially registered and tracked. Camels are an integral part of life on the Arabian Peninsula, where camel racing and show pageants showcase the pedigree of animals that are purchased and sold at auction for huge sums. Due to growing issues about animal health, vaccines are also projected to see a significant rise in the coming years. As disease-prevention medicines evolve, the development of animal vaccinations is driving the market growth. Due to a growth in the number of livestock diseases, the pharmaceuticals business is predicted to grow dramatically over the forecast period as this has propelled the government and major players to invest in the market.
Increased R&D Investments in Animal Immunization
Some of the important driving factors responsible for market expansion are technical developments and the consequent introduction of animal vaccines. Since they were first presented to the general public, animal immunization has experienced significant R&D advancements.
Animal immunization with pathogens that have been routinely attenuated and inactivated has made significant contributions to the protection of animal and human health. For instance, in September 2020, a hospital near the city of Buraydah in Saudi Arabia's central Qassim region was opened in July 2020 with an expenditure of 137 million Saudi riyals ($36.5 million). It is reported to be the world's largest centre for treating ill camels, with a surface area of 70,000 square meters. Furthermore, the government announced that a new veterinary healthcare platform will open in Abu Dhabi in April 2022, marking a significant milestone for the nation's animal healthcare business. A cutting-edge vaccine production facility and two state-of-the-art veterinary clinics will form the foundation of the medical platform. The facilities will strengthen Abu Dhabi's status as a regional superpower in high-end veterinary care for horses and camels, as well as provide the most advanced technological animal vaccinations for the Middle East and Africa (MEA) area, once they are functional. Companies are taking advantage of Abu Dhabi's great potential market for animal vaccine production while also ensuring the health and well-being of treasured animals such as horses and camels by forming a joint venture with E20.
Furthermore, an increase in the number of livestock exports in the country will further propel the market growth during the projected timeframe. For instance, Sudan stated in April 2022 that it started exporting livestock to Saudi Arabia, the country's primary export, after extending a health protocol. According to government data, Sudan has more than 107 million cattle, and livestock exports are a significant source of foreign exchange, raking in over $1 billion in revenue.
Injectable market to grow steadily.
Vaccines continue to play an increasingly important role in animal disease prevention and control programs. Pets and farm animals continue to benefit from critical medications that prevent or reduce clinical indications of disease owing to innovative research and the creation of safe, effective, and high-quality vaccinations. Although the pet market is not that prevalent in Saudi Arabia but has a huge number of stray animals and farm animals. The high number of stray cats, dogs, and other animals has led to several rescue centres and shelters. Recently, the Karbasha, a nonprofit organization and the first social facility approved by the Ministry of Human Resources and Social Development (Saudi Arabia), hosted a program with students to save abandoned animals in Riyadh. Such programs are anticipated to upsurge in the forecast period. With is the demand for injectable vaccines is anticipated to increase. Increasing research and development and raising awareness for zoonotic disease, especially after experiencing a pandemic, have led to an increase in injectable vaccines. According to the OIE WAHIS database, zero human cases of zoonotic disease were detected for the 2019 calendar year.
The COVID-19 pandemic resiliently impacted the veterinary vaccine market in Saudi Arabia. The robust outbreak of the virus and its exponential spread resulted in the implementation of a nationwide lockdown. Stuck at home, anxiety and consciousness increase among people, resulting in an increase in the adoption of pets. However, owing to trade restrictions and disruption in operation across the meat production industry, the population of livestock was impacted with impacted the veterinary vaccine market.
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Powers of Buyers
4.3.3. Threat of Substitutes
4.3.4. The threat of New Entrants
4.3.5. Competitive Rivalry in Industry
4.4. Industry Value Chain Analysis
5. SAUDI ARABIA VETERINARY VACCINES MARKET BY TYPE
5.2. Livestock Vaccines
5.2.1. Bovine Vaccines
5.2.2. Poultry Vaccines
5.2.3. Porcine Vaccines
5.3. Companion Animal Vaccines
5.3.1. Canine Vaccines
5.3.2. Feline Vaccines
5.3.3. Equine Vaccines
6. SAUDI ARABIA VETERINARY VACCINES MARKET BY TECHNOLOGY
6.2. Live Attenuated Vaccines
6.3. Inactivated Vaccines
6.4. Toxoid Vaccines
6.5. Recombinant Vaccines
7. SAUDI ARABIA VETERINARY VACCINES MARKET BY ROUTE OF ADMINISTRATION
7.2. Injectable Vaccines
7.3. Intranasal Vaccines
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Merck & Co.
8.2. Boehringer Ingelheim International GmbH
8.3. Ceva Santé Animale
8.4. Elanco Animal Health Incorporated
8.6. Al-Emar International (ARASCO)
Boehringer Ingelheim International GmbH
Ceva Santé Animale
Elanco Animal Health Incorporated
Al-Emar International (ARASCO)
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.